INR101

DRUG3 trials

Sponsors

Yunhe Pharmaceutical (Tianjin) Co., Ltd

Conditions

Healthy Male SubjectsProstate CancerProstate Cancer RecurrentSuspected Prostate Cancer

Phase 1

A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer

CompletedNCT06472531

Yunhe Pharmaceutical (Tianjin) Co., LtdHealthy Male Subjects, Suspected Prostate Cancer

Start: 2024-05-23End: 2024-10-10Updated: 2024-10-30

Phase 3

A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment

Not yet recruitingNCT06922929

Yunhe Pharmaceutical (Tianjin) Co., LtdProstate Cancer Recurrent

Start: 2025-04-30End: 2027-04-30Target: 110Updated: 2025-04-11

Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.

Not yet recruitingNCT06922903

Yunhe Pharmaceutical (Tianjin) Co., LtdProstate Cancer

Start: 2025-04-30End: 2026-05-31Target: 240Updated: 2025-04-13